Skip to content

Relationship between IL6 and fatigue induced by radiotherapy and chemotherapy in patients treated with Melatonin drug

The evaluation of relationship between IL6( Interleukin-6) serum level and fatigue induced by adjuvant radiotherapy and chemotherapy in women with breast cancer treated with Melatonin drug: A clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180426039421N2
Enrollment
64
Registered
2018-09-22
Start date
2018-10-07
Completion date
Unknown
Last updated
2018-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cance

Interventions

Intervention 1: Intervention group: Oral Melatonin drug 6 mg( 2 capsule of 3 mg) every night from 3 to 7 days before the start of Adjuvant treatmentwill be used until the disease progresses. Intervent

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Breast Cancer Stages I, II, III According to Pathological Reports Patients at least 18 Years Old Have Signed a Written Consent Recevieng Adjuvant Chemotherapy and Radiotherapy No Untreated Hypercalcemia No Systolic Blood Pressure Less Than 100 mm Hg No Warfarin Consumption No Methylphenidate Consumption No Sleep Pills During Melatonin Use No TSH>5/5 or <0/5 No Pregnancy or Breastfeeding

Exclusion criteria

Exclusion criteria: Expired During Treatment Stop Using Melatonin during Treatment

Design outcomes

Primary

MeasureTime frame
Fatigue severity in the BFI questionnaire. Timepoint: 4 weeks after last adjuvant treatment session. Method of measurement: Brief Fatigue Inventory( BFI) questionnaire.;IL6( interleukin 6) serum level. Timepoint: 4 weeks after last adjuvant treatment session. Method of measurement: Solid phase sandwich ELISA method.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Kesht pour amlashi

Hamedan University of Medical Sciences

Zahraka@mail.com+98 81 3838 1076

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026